Navigation Links
NeurogesX to Present at Upcoming Fall Conferences
Date:9/2/2009

ward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.               The Ruth Group
    Stephen Ghiglieri             Sara Pellegrino (investors)
    Chief Financial Officer       (646) 536-7002
    (650) 358-3310                spellegrino@theruthgroup.com

                                  Jason Rando (media)
                                  (646) 536-7025
                                  '/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX Appoints New Board Director and Audit Committee Chairman
2. NeurogesX Reports Second Quarter 2009 Results
3. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
4. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
5. NeurogesX Added to Russell 3000 Index
6. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
7. NeurogesX to Present at Needham Life Sciences Conference
8. NeurogesX Receives European Commission Approval for Qutenza(TM)
9. NeurogesX Reports First Quarter 2009 Results
10. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
11. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , August 4, 2015 ... Market Research, titled, "World Cardiac Biomarker - Market ... market would generate the revenue of $2,085.9 million ... 2015 to 2020. Cardiac Troponins (T, I) would ... period due to high sensitivity and specificity. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... point-of-care (POC) diagnostic tests – today announced that Robert A. Gregg, PhD, has ... has more than 30 years of relevant experience and remarkable achievements in the ...
(Date:8/4/2015)... CAMBRIDGE, Mass. , Aug. 4, 2015  Blueprint ... and developing highly selective kinase drugs for genomically defined ... executive officer, will present a company overview at the ... 2015 at 1:20 p.m. EDT. A live ... the Investors section of the Blueprint Medicines website at ...
(Date:8/4/2015)... ... 04, 2015 , ... On August 4, 2015, the White House will host ... across the United States to talk about their experiences with innovation and present their ... be among the attendees. , One of the day’s aims is to grow the ...
Breaking Biology Technology:Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... 1 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin ... leading manufacturer and distributor in China of ... medical industry and,glucose and starch products for ... appointment of Ms. Melody Shi as its ...
... Therapeutics (Amex:,CXM) announced today that Richard A. Schatz, M.D., ... early pioneer of coronary stent,technology and is best known ... Palmaz-Schatz stent. Dr. Schatz is Research Director of,Cardiovascular Interventions ... in La Jolla, California. He is also active in ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Shengtai Pharmaceutical, Inc. Appoints New CFO 2Shengtai Pharmaceutical, Inc. Appoints New CFO 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 2Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 3Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board 4
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... York City/Great Neck, NY) The Brain & Behavior ... Research on Schizophrenia and Depression) has announced approximately $4 ... has invested close to $300 million in research to ... for mental illness. From about 500 applicants, forty ...
... pathogen that causes Lyme Diseaseunlike any other known organismcan ... needs to make proteins and enzymes. Instead of iron, ... thus eluding immune system defenses that protect the body ... Borrelia burgdorferi requires unusually high levels of ...
... researchers have taken an important step in the ongoing battle ... a breakthrough device that can immediately detect the presence of ... lighter than a cellphone and about the size of a ... measure nicotine in the air. A sensor chip then records ...
Cached Biology News:Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 2Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 3Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 4Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 5Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 6Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 7Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 8Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 9Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 10Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 11Brain & Behavior Research Foundation awards nearly $4 million in new NARSAD grants 12Scientists reveal quirky feature of Lyme disease bacteria 2Scientists reveal quirky feature of Lyme disease bacteria 3Scientists create new tools for battling secondhand smoke 2Scientists create new tools for battling secondhand smoke 3
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: